LABP-66 / AbbVie - LARVOL DELTA

Validating a novel negative regulator of inflammasome activation to drive resolution of inflammation in Parkinson’s disease (WPC 2026) - "Importantly, NLRX1 agonists are under clinical evaluation: NX-13 for IBD and LABP-66 for MS, highlighting the translational potential of targeting NLRX1. Future studies will test LABP-72 for its ability to halt PD progression, supporting its potential as a disease-modifying therapeutic target."

CNS Disorders • Inflammation • Movement Disorders • Parkinson's Disease • CASP3 • CASP7 • HSPD1 • NLRP3 • RPS23 • TNFA • TRIM21

NLRX1 limits inflammatory neurodegeneration in the anterior visual pathway. (PubMed, J Neuroinflammation) - "The novel pharmacologic NLRX1 activators NX-13 and LABP-66 decreased LPS-mediated gene expression of inflammatory cytokines and chemokines in mixed glial cultures...This study highlights that NLRX1 could serve as a promising target for neuroprotection in progressive MS and other neurodegenerative diseases. Further studies are needed to better understand the cell-specific mechanisms underlying the neuroprotective role of NLRX1 in response to inflammation in the CNS."

Journal • CNS Disorders • Immunology • Inflammation • Multiple Sclerosis • Optic Neuritis • IFNG

The Innate Immune Regulator, NLRX1, Suppresses Glial Inflammation and Neurodegeneration in the EAE Models (ACTRIMS Forum 2023) - "Our findings suggest that NLRX1 functions as a regulator of the innate immune response and suppresses glial inflammation and neurodegeneration. Our ongoing experiments using an NLRX1 agonist, LABP-66, in EAE mice suggest that therapeutic targeting of this pathway could be used to boost/restore the anti-inflammatory function of NLRX1 to limit CNS inflammation and neurodegeneration."

CNS Disorders • Immunology • Inflammation • Multiple Sclerosis • Ocular Inflammation • Ophthalmology • Optic Neuritis • NF-κβ

The Novel NLRX1 Activator LABP-66 Attenuates Glial Activation and Limits Neurodegeneration in Late Stage Experimental Encephalomyelitis (ACTRIMS Forum 2023) - "These data suggest that pharmacologic NLRX1 activators attenuate glial innate immune activation and have the potential to limit inflammatory neurodegeneration in chronic CNS inflammatory diseases such as multiple sclerosis. These preliminary studies further support the potential therapeutic targeting of NLRX1 in multiple sclerosis. Ongoing studies will test the therapeutic potential of the NLRX1 activator LABP-66 to downregulate neurotoxic glia in vivo in EAE."

CNS Disorders • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Multiple Sclerosis • Ulcerative Colitis • CCL20 • CXCL1 • IL1A • NF-κβ • NOS2 • TNFA